{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T04:16:39Z","timestamp":1772856999904,"version":"3.50.1"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Monoclonal antibodies against programmed cell death protein-1 (PD-1)\/programmed death-ligand-1 (PD-L1) have emerged as critical tools in cancer treatment. However, concerns regarding their potential cutaneous and mucosal toxicity, along with severe complications, have drawn clinical attention. Further research is warranted to investigate the adverse reactions and treatment strategies associated with PD-1 monoclonal antibodies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We present a detailed case report of a laryngeal cancer patient who developed toxic epidermal necrolysis (TEN) after treatment with PD-1 monoclonal antibody. We analyzed the etiology, diagnosis, and treatment approaches by integrating clinical manifestations, pathological examinations, and literature research.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>After PD-1 monoclonal antibody therapy, the patient exhibited systemic rash, bullae, and epidermal detachment, which subsequently involved the tracheal and bronchial mucosa, resulting in dyspnea. The patient recovered after treatments with steroids, macrolides, immunoglobulins, and etanercept, along with repeated removal of scabs via bronchoscopy. Literature reviewing suggests a potential association between PD-1 monoclonal antibodies and the pathogenesis of Steven Johnson\u2019s Syndrome (SJS) and Toxic epidermal necrolysis (TEN), possibly due to immune dysregulation. Treatment consists of immediate discontinuation of suspicious drugs, essential supportive therapy, and systemic corticosteroid administration, with the addition of immunosuppressants and\/or immunoglobulins needed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The mucocutaneous toxicity induced by PD-1 monoclonal antibodies is not limited to the surface of the skin but also in deep mucosal layers, potentially leading to life-threatening complications. Therefore, when using PD-1 monoclonal antibodies, clinicians should closely monitor adverse events and apply appropriate treatments as soon as possible to prevent severe complications.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1454015","type":"journal-article","created":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T04:42:16Z","timestamp":1729226536000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Immune-related toxic epidermal necrolysis affecting trachea mucosal epithelium: a case report and literature review"],"prefix":"10.3389","volume":"15","author":[{"given":"Mingbo","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxiao","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bicheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.yrtph.2018.09.028","article-title":"Are skin sensitisation test methods relevant for proteins?","volume":"99","author":"Basketter","year":"2018","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1001\/jamaoncol.2019.0402","article-title":"Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer","volume":"5","author":"Berner","year":"2019","journal-title":"JAMA Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1111\/jdv.16311","article-title":"Cutaneous adverse events: a predictor of tumour response under anti-PD-1 therapy for metastatic melanoma, a cohort analysis of 189 patients","volume":"34","author":"Bottlaender","year":"2020","journal-title":"J. Eur. Acad. Dermatol Venereol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.3389\/fimmu.2020.01259","article-title":"Multiple roles for chemokines in neutrophil biology","volume":"11","author":"Capucetti","year":"2020","journal-title":"Front. Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"5956","DOI":"10.1158\/1078-0432.CCR-16-2033","article-title":"Anti-PD1-Induced pneumonitis: capturing the hidden enemy","volume":"22","author":"Castanon","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.2147\/CMAR.S163391","article-title":"Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies","volume":"10","author":"Chen","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e007675","DOI":"10.1136\/jitc-2023-007675","article-title":"Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy","volume":"12","author":"Chen","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"13620","DOI":"10.1038\/s41598-023-40812-3","article-title":"Correlations between histopathologic findings, serum biomarker levels, and clinical outcomes in Stevens-Johnson syndrome\/toxic epidermal necrolysis (SJS\/TEN)","volume":"13","author":"Chuenwipasakul","year":"2023","journal-title":"Sci. Rep."},{"key":"B9","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.currproblcancer.2016.12.001","article-title":"Cutaneous adverse effects of the immune checkpoint inhibitors","volume":"41","author":"Collins","year":"2017","journal-title":"Curr. Probl. Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"935","DOI":"10.3760\/cma.j.cn112152-20220213-00098","article-title":"Chinese expert consensus on diagnosis and treatment of neurologic immune-related adverse events associated with immune checkpoint inhibitors (2022 edition)","volume":"44","year":"2022","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"B11","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1001\/archderm.129.4.466","article-title":"Cutaneous T-cell recruitment in toxic epidermal necrolysis. Further evidence of CD8+ lymphocyte involvement","volume":"129","author":"Correia","year":"1993","journal-title":"Archives dermatology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/cup.12858","article-title":"Diverse types of dermatologic toxicities from immune checkpoint blockade therapy","volume":"44","author":"Curry","year":"2017","journal-title":"J. Cutan. Pathol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1080\/09546634.2021.1937477","article-title":"Development of immunity-related adverse events correlates with baseline clinical factors, survival and response to anti-PD-1 treatment in patients with inoperable or metastatic melanoma","volume":"33","author":"Cybulska-Stopa","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"B14","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/ajd.14262","article-title":"Severe cutaneous adverse reactions associated with the immune checkpoint inhibitors: a case\/non-case analysis using the Food and Drug Administration Adverse Event Reporting System","volume":"65","author":"Godfrey","year":"2024","journal-title":"Australas. J. Dermatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e47457","DOI":"10.7759\/cureus.47457","article-title":"A diagnostic quandary: carboplatin-paclitaxel-induced stevens-johnson syndrome in a rare case of carcinosarcoma of the esophagus and review of the literature","volume":"15","author":"Gokulanathan","year":"2023","journal-title":"Cureus"},{"key":"B16","doi-asserted-by":"publisher","first-page":"4023","DOI":"10.1158\/1078-0432.CCR-15-2872","article-title":"Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy","volume":"22","author":"Goldinger","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"102536","DOI":"10.1016\/j.eclinm.2024.102536","article-title":"Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade-a worldwide perspective","volume":"70","author":"Gougis","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B18","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-024-00514-0","article-title":"Severe cutaneous adverse reactions","volume":"10","author":"Hung","year":"2024","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B19","doi-asserted-by":"publisher","first-page":"717","DOI":"10.3760\/cma.j.issn.0253-2727.2021.09.002","article-title":"Chinese expert consensus on prevention and treatment of immunotherapeutic and molecular targeted agents-related infections in patients with hematological malignancies (2021 version)","volume":"42","year":"2021","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B20","doi-asserted-by":"publisher","first-page":"CD013130","DOI":"10.1002\/14651858.CD013130.pub2","article-title":"Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS\/TEN overlap syndrome","volume":"3","author":"Jacobsen","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"B21","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1021\/acs.chemrestox.2c00414","article-title":"Characterization of drug-specific CD4(+) T-cells reveals possible roles of HLA class II in the pathogenesis of carbamazepine hypersensitivity reactions","volume":"36","author":"Jaruthamsophon","year":"2023","journal-title":"Chem. Res. Toxicol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1400097","DOI":"10.3389\/fimmu.2024.1400097","article-title":"Case report: inflammatory sternoclavicular joint arthritis induced by an immune checkpoint inhibitor with remarkable responsiveness to infliximab","volume":"15","author":"Kachi","year":"2024","journal-title":"Front. Immunol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s13691-024-00660-y","article-title":"Capecitabine and oxaliplatin induced Steven-Johnson syndrome following nivolumab in a patient of metastatic esophageal carcinoma","volume":"13","author":"Kumar","year":"2024","journal-title":"Int. Cancer Conf. J."},{"key":"B24","doi-asserted-by":"publisher","first-page":"152440","DOI":"10.1016\/j.semarthrit.2024.152440","article-title":"A scoping review of vasculitis as an immune-related adverse event from checkpoint inhibitor therapy of cancer: unraveling the complexities at the intersection of immunology and vascular pathology","volume":"66","author":"Lee","year":"2024","journal-title":"Semin. Arthritis Rheum."},{"key":"B25","doi-asserted-by":"publisher","first-page":"663","DOI":"10.2147\/CCID.S451386","article-title":"Immune checkpoint inhibitor-associated systemic sclerosis in the treatment of a small cell lung cancer patient with durvalumab: a case report","volume":"17","author":"Li","year":"2024","journal-title":"Clin. Cosmet. Investig. Dermatol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/s12672-023-00749-5","article-title":"Case report: a successful treatment with immune checkpoint inhibitors was associated with severe dermatologic toxicities in a patient with double primary malignancies","volume":"14","author":"Li","year":"","journal-title":"Discov. Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"912168","DOI":"10.3389\/fonc.2023.912168","article-title":"Case Report: sintilimab-induced Stevens-Johnson Syndrome in a patient with advanced lung adenocarcinoma","volume":"13","author":"Li","year":"","journal-title":"Front. Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/CJI.0000000000000302","article-title":"Combination therapy of ipilimumab and nivolumab-associated toxic epidermal necrolysis (TEN) in a patient with metastatic melanoma: a case report and literature review","volume":"43","author":"Logan","year":"2020","journal-title":"J. Immunother. (Hagerstown, Md 1997)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1076473","DOI":"10.3389\/fphar.2023.1076473","article-title":"Selected cutaneous adverse events in patients treated with ICI monotherapy and combination therapy: a retrospective pharmacovigilance study and meta-analysis","volume":"14","author":"Lu","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s40001-023-01142-2","article-title":"Photodistributed Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and proposal for a new diagnostic classification","volume":"28","author":"McKinley","year":"2023","journal-title":"Eur. J. Med. Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1111\/all.15814","article-title":"The allopurinol metabolite, oxypurinol, drives oligoclonal expansions of drug-reactive T cells in resolved hypersensitivity cases and drug-naive healthy donors","volume":"78","author":"Mifsud","year":"2023","journal-title":"Allergy"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e121","DOI":"10.1016\/j.jaad.2012.12.963","article-title":"The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis","volume":"69","author":"Minkis","year":"2013","journal-title":"J. Am. Acad. Dermatol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaut.2014.06.005","article-title":"Programmed cell death 1 (PD-1) regulates the effector function of CD8 T cells via PD-L1 expressed on target keratinocytes","volume":"53","author":"Okiyama","year":"2014","journal-title":"J. Autoimmun."},{"key":"B34","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.clgc.2019.01.021","article-title":"Myalgia and arthralgia immune-related adverse events (irAEs) in patients with genitourinary malignancies treated with immune checkpoint inhibitors","volume":"17","author":"Ornstein","year":"2019","journal-title":"Clin. Genitourin. cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"9959","DOI":"10.1073\/pnas.1207934109","article-title":"Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire","volume":"109","author":"Ostrov","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B36","doi-asserted-by":"publisher","first-page":"3000605231223059","DOI":"10.1177\/03000605231223059","article-title":"Tumor necrosis factor-\u03b1 inhibitor for successful treatment of toxic epidermal necrolysis with severe infection: a case series","volume":"52","author":"Peng","year":"2024","journal-title":"J. Int. Med. Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/WOX.0b013e3181778282","article-title":"The p-i concept: pharmacological interaction of drugs with immune receptors","volume":"1","author":"Pichler","year":"2008","journal-title":"World Allergy Organ J."},{"key":"B38","doi-asserted-by":"publisher","first-page":"102751","DOI":"10.1016\/j.ctrv.2024.102751","article-title":"Toxicity of immunotherapy combinations with chemotherapy across tumor indications: current knowledge and practical recommendations","volume":"127","author":"Rached","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"B39","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/BF00406477","article-title":"Lymphopenia and abnormal balance of T-lymphocyte subpopulations in toxic epidermal necrolysis","volume":"277","author":"Roujeau","year":"1985","journal-title":"Arch. Dermatol Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"114028","DOI":"10.1016\/j.ejca.2024.114028","article-title":"Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors","volume":"203","author":"Ruf","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"B41","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/1346-8138.17039","article-title":"Immune checkpoint inhibitor-induced epidermal necrolysis: a narrative review evaluating demographics, clinical features, and culprit medications","volume":"51","author":"Satoh","year":"2024","journal-title":"J. Dermatol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ejca.2017.03.026","article-title":"Pembrolizumab-induced Stevens-Johnson syndrome in non-melanoma patients","volume":"81","author":"Saw","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"B43","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/ajd.14329","article-title":"A systematic review of case-control studies of cytokines in blister fluid and skin tissue of patients with Stevens Johnson syndrome and toxic epidermal necrolysis","volume":"65","author":"Stewart","year":"2024","journal-title":"Australas. J. Dermatol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/CJI.0000000000000190","article-title":"Life-threatening autoimmune cardiomyopathy reproducibly induced in a patient by checkpoint inhibitor therapy","volume":"41","author":"Tajmir-Riahi","year":"2018","journal-title":"J. Immunother. (Hagerstown, Md 1997)"},{"key":"B45","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/cup.12876","article-title":"Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy","volume":"44","author":"Vivar","year":"2017","journal-title":"J. Cutan. Pathol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"17588359231187205","DOI":"10.1177\/17588359231187205","article-title":"Chinese expert consensus recommendations for the administration of immune checkpoint inhibitors to special cancer patient populations","volume":"15","author":"Wang","year":"2023","journal-title":"Ther. Adv. Med. Oncol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1071983","DOI":"10.3389\/fimmu.2023.1071983","article-title":"Cutaneous manifestations associated with immune checkpoint inhibitors","volume":"14","author":"Watanabe","year":"2023","journal-title":"Front. Immunol."},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.87288","article-title":"Exploratory mass cytometry analysis reveals immunophenotypes of cancer treatment-related pneumonitis","volume":"12","author":"Yanagihara","year":"2024","journal-title":"Elife"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1065137","DOI":"10.3389\/fonc.2022.1065137","article-title":"Case Report: toxic epidermal necrolysis associated with sintilimab in a patient with relapsed thymic carcinoma","volume":"12","author":"Yang","year":"2022","journal-title":"Front. Oncol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1454015\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T04:42:19Z","timestamp":1729226539000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1454015\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,18]]},"references-count":50,"alternative-id":["10.3389\/fphar.2024.1454015"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1454015","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,18]]},"article-number":"1454015"}}